Dr Amol Akhade· @SuyogCancer · X·· 2 days agoScore90
Body · original
Probably first negative trial for Trastuzumab deruxtecan. Talent trial. For early stage HR positive Her2 low EBC @myESMO #esmo26 @OncoAlert
2739 views · 30 likes · 8 reposts · 1 reply
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgReplies in this thread
- Santhosh Ambika@RenoHemonc
@SuyogCancer @myESMO @OncoAlert Neoadj single agent TDxd was not impressive even in Her2+
Source: Dr Amol Akhade · x.com